New ALS drug usnoflast faces crucial test in 240 patients
NCT ID NCT07023835
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 26 times
Summary
This study tests whether the drug usnoflast can slow the progression of ALS, a serious nerve disease that weakens muscles over time. About 240 adults with ALS will receive either usnoflast or a placebo for 36 weeks. Researchers will measure changes in daily function and survival to see if the drug helps control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS (ALS) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Zydus 009
Pittsburgh, Pennsylvania, 15212, United States
-
Zydus 100
Québec, Quebec, QC H4A 3T2, Canada
-
Zydus 101
Toronto, Ontario, ON M4N 3M5, Canada
-
Zydus US001
Dallas, Texas, 75206, United States
-
Zydus US002
Houston, Texas, 77030, United States
-
Zydus US003
Winston-Salem, North Carolina, 27157, United States
-
Zydus US004
Richmond, Virginia, 23298, United States
-
Zydus US005
New Britain, Connecticut, 06053, United States
-
Zydus US006
Detroit, Michigan, 48202, United States
-
Zydus US007
Atlanta, Georgia, 30322, United States
-
Zydus US008
Orange, California, 92868, United States
-
Zydus US010
Boston, Massachusetts, 02114, United States
-
Zydus US011
Seattle, Washington, 98122, United States
-
Zydus US012
Tampa, Florida, 80045, United States
-
Zydus US013
San Francisco, California, 94109, United States
-
Zydus US014
Lincoln, Nebraska, 68510, United States
-
Zydus US015
La Jolla, California, 92037, United States
Conditions
Explore the condition pages connected to this study.